Adial Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $10.5M
- Price
- $3.99
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.25%
- Volume
- 4.4K
About
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
Quick stats
Shares outstanding2.6M
Computed float1.6M
Float / shares59.5%
Cash runway (months)4
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001513525
Websitehttps://www.adial.com
AI Summary
AI-generated1/9
minorneutralother
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adial Pharmaceuticals granted an inducement stock option to purchase 155,446 shares at $4.22 per share to a new employee, disclosed under Nasdaq Listing Rule 5635(c)(4).
The option has a ten-year term, vests over four years with 25% cliff-vesting at the first anniversary, and was made outside the company's equity plans.
Adial is a clinical-stage biopharma whose focus has shifted to inflammatory diseases following its June 2026 acquisition of Azora Therapeutics, with lead program AT177 in IND-enabling studies for ulcerative colitis.
Red flags
- minor equity dilution (~155K shares) from out-of-plan inducement grant